PRKAA2 and ductal breast carcinoma in situ: Among these, a specific upregulated kinase in DCIS (DCIS versus Normal, p < 0.05, DH versus Normal, p > 0.05, IDC versus Normal, p > 0.05), PRKAA2, was a target of an approved inhibitor (Figure S3H, Supporting Information).